Product Description
Mechanisms of Action: B7-H4 Inhibitor
Novel Mechanism: Yes
Modality: Antibody Drug Conjugate
Route of Administration: N/A
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: GlaxoSmithKline
Company Location: BRENTFORD MIDDLESEX X0 TW8 9GS
Company CEO: Emma Walmsley
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Australia, Belgium, Canada, Finland, Italy, Japan, Netherlands, Spain, Sweden, United Kingdom, United States
Active Clinical Trial Count: 2
Highest Development Phases
Phase 1: Oncology Solid Tumor Unspecified
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
jRCT2031240279 | P1 |
Not yet recruiting |
Oncology Solid Tumor Unspecified |
2027-01-21 |
|
NCT06431594 | P1 |
Recruiting |
Oncology Solid Tumor Unspecified |
2026-10-15 |